Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

Por Oriol Iborra-Egea, MSc, Evelyn Santiago-Vacas, MD, Salva R. Yurista, MD, Josep Lupón, MD, PhD, Milton Packer, MD, Stephane Heymans, MD, Faiez Zannad, MD, Javed Butler, MD, Domingo Pascual-Figal, MD, Antonio Lax, PhD, Julio Núñez, MD, PhD, Rudolf A. de Boer, MD, PhD, Antoni Bayés-Genís, MD, PhD
Publicado em 2019-11-01